ArticleInfection and drug resistance2025
Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amphotericin B Colloidal Dispersion Is Effective and Safe for the Treatment of Invasive Aspergillosis in Chinese Patients with Hematologic Disease: A Multicenter, Prospective, Observational, Real-World Study.Drug design, development and therapy · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the efficacy and safety of amphotericin B colloidal dispersion (ABCD) in treating invasive pulmonary fungal disease (IPFD) through nebulized inhalation combined with intravenous therapy. Methods: Patients diagnosed with IPFD who received ABCD from October 2023 to March 2024 were retrospectively enrolled. The treatment protocol for patient was determined by clinicians according to the patient's condition and clinical practice. According to the treatment protocol, patients were divided into two groups: the ABCD nebulized inhalation combined with intravenous injection (combined therapy group) and the ABCD intravenous injection (intravenous therapy group). Clinical characteristics, ABCD administration (dose and duration), treatment outcomes (favorable response rate), and adverse events (AEs) were compared between the two groups. Results: Thirty-two patients were included, with 16 in each group. No significant differences were observed in the clinical characteristics between the two groups. In the combined therapy group, the numbers of proven, probable, and possible cases were 4 (25.00%), 7 (43.75%), and 5 (31.25%), respectively. In the intravenous injection treatment group, 1 (6.25%), 11 (68.75%), and 4 (25.00%) patients were proven, probable, and possible, respectively. The total dose of ABCD was slightly lower in the combined therapy group than in the intravenous therapy group (1675 vs 1800, Conclusion: The efficacy of ABCD nebulized inhalation combined with intravenous injection was superior to intravenous injection of ABCD alone in the treatment of IPFD, with comparable safety and shortened medication time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.